Nicholas Galakatos - Net Worth and Insider Trading
Nicholas Galakatos Net Worth
The estimated net worth of Nicholas Galakatos is at least $7 Million dollars as of 2024-04-25. Nicholas Galakatos is the Director, 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $4 Million. Nicholas Galakatos is the 10% Owner of Rigel Pharmaceuticals Inc and owns about 1,833,597 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $2 Million. Nicholas Galakatos is also the Director, 10% Owner of NanoString Technologies Inc and owns about 4,036,025 shares of NanoString Technologies Inc (NSTGQ) stock worth over $1 Million. Besides these, Nicholas Galakatos also holds Astria Therapeutics Inc (ATXS) , IVERIC bio Inc (ISEE) , Affymax Inc (AFFY) . Details can be seen in Nicholas Galakatos's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Nicholas Galakatos has not made any transactions after 2018-09-28 and currently still holds the listed stock(s).
Transaction Summary of Nicholas Galakatos
Nicholas Galakatos Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Nicholas Galakatos owns 28 companies in total, including Praxis Precision Medicines Inc (PRAX) , Entasis Therapeutics Holdings Inc (ETTX) , and NanoString Technologies Inc (NSTGQ) among others .
Click here to see the complete history of Nicholas Galakatos’s form 4 insider trades.
Insider Ownership Summary of Nicholas Galakatos
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
PRAX | Praxis Precision Medicines Inc | 2020-10-15 | director |
ETTX | Entasis Therapeutics Holdings Inc | 2019-06-19 | director |
NSTGQ | NanoString Technologies Inc | 2018-09-17 | director & 10 percent owner |
FTSV | Forty Seven Inc | 2018-07-02 | 10 percent owner |
VERO | Venus Concept Inc | 2017-10-11 | 10 percent owner |
RDUS | Radius Health Inc | 2011-05-17 | 10 percent owner |
ATXS | Astria Therapeutics Inc | 2015-06-30 | director & 10 percent owner |
TLOG | TetraLogic Pharmaceuticals Corp | 2016-02-08 | 10 percent owner |
ISEE | IVERIC bio Inc | 2016-01-11 | director & 10 percent owner |
OXFD | Oxford Immunotec Global PLC | 2015-06-15 | 10 percent owner |
AERI | Aerie Pharmaceuticals Inc | 2013-10-25 | 10 percent owner |
SIENQ | Sientra Inc | 2014-10-28 | 10 percent owner |
PTLA | Portola Pharmaceuticals Inc | 2014-06-27 | director |
GMED | Globus Medical Inc | 2012-08-02 | other: Managing dir. of GP |
HGENQ | Humanigen Inc | 2012-08-11 | 10 percent owner |
ACHN | Achillion Pharmaceuticals Inc | 2012-06-04 | 10 percent owner |
EPRSQ | EPIRUS Biopharmaceuticals Inc | 2011-10-27 | 10 percent owner |
ZGNX | Zogenix Inc | 2011-09-16 | 10 percent owner |
AVEO | AVEO Pharmaceuticals Inc | 2010-03-11 | director & 10 percent owner |
RSLS | Reshape Lifesciences Inc | 2010-12-14 | other: Former 10% Owner |
ALT | Altimmune Inc | 2007-08-03 | other: See explanation below |
ARYX | ARYx Therapeutics Inc | 2010-09-30 | 10 percent owner |
LGNZZ | Metabasis Therapeutics Inc | 2010-01-27 | 10 percent owner |
PARD | Poniard Pharmaceuticals Inc | 2009-11-05 | 10 percent owner |
AFFY | Affymax Inc | 2009-05-28 | director & 10 percent owner |
RIGL | Rigel Pharmaceuticals Inc | 2004-07-02 | 10 percent owner |
CYCC | Cyclacel Pharmaceuticals Inc | 2004-03-10 | 10 percent owner |
TALS | Talaris Therapeutics Inc | 2021-05-06 | director |
Nicholas Galakatos Latest Holdings Summary
Nicholas Galakatos currently owns a total of 6 stocks. Among these stocks, Nicholas Galakatos owns 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $4 Million and a weighting of 47.63%. Nicholas Galakatos owns 1,833,597 shares of Rigel Pharmaceuticals Inc (RIGL) as of July 2, 2004, with a value of $2 Million and a weighting of 26.53%. Nicholas Galakatos also owns 4,036,025 shares of NanoString Technologies Inc (NSTGQ) as of September 17, 2018, with a value of $1 Million and a weighting of 15.15%. The other 3 stocks Astria Therapeutics Inc (ATXS) , IVERIC bio Inc (ISEE) , Affymax Inc (AFFY) have a combined weighting of 10.69% among all his current holdings.
Latest Holdings of Nicholas Galakatos
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 1,623,405 | 2.19 | 3,555,257 |
RIGL | Rigel Pharmaceuticals Inc | 2004-07-02 | 1,833,597 | 1.08 | 1,980,285 |
NSTGQ | NanoString Technologies Inc | 2018-09-17 | 4,036,025 | 0.28 | 1,130,491 |
ATXS | Astria Therapeutics Inc | 2015-06-30 | 45,875 | 9.02 | 413,563 |
ISEE | IVERIC bio Inc | 2016-01-11 | 9,629 | 39.95 | 384,679 |
AFFY | Affymax Inc | 2006-12-14 | 49,998 | 0.00 | 35 |
Holding Weightings of Nicholas Galakatos
Nicholas Galakatos Form 4 Trading Tracker
According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 453,395 shares on September 28, 2018, which cost Nicholas Galakatos around $7 Million.
According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 1,652 shares on July 2, 2004, which brought Nicholas Galakatos around $25,325.
According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in NanoString Technologies Inc (NSTGQ) over the past 5 years. The most-recent trade in NanoString Technologies Inc is the sale of 85,823 shares on September 17, 2018, which brought Nicholas Galakatos around $1 Million.
More details on Nicholas Galakatos's insider transactions can be found in the Insider Trading History of Nicholas Galakatos table.Insider Trading History of Nicholas Galakatos
- 1
Nicholas Galakatos Trading Performance
GuruFocus tracks the stock performance after each of Nicholas Galakatos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Nicholas Galakatos is -28.87%. GuruFocus also compares Nicholas Galakatos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Nicholas Galakatos within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Nicholas Galakatos's insider trading performs compared to the benchmark.
Performance of Nicholas Galakatos
Average Return
-27.35%
Outperforming Transactions
33%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | -5.52 | -28.87 | -21.69 | -27.35 | -34.56 | -24.3 |
Relative Return to S&P 500(%) | -4.96 | -24.82 | -24.05 | -34.23 | -42.05 | -35.22 |
Nicholas Galakatos Ownership Network
Ownership Network List of Nicholas Galakatos
Ownership Network Relation of Nicholas Galakatos
Nicholas Galakatos Owned Company Details
What does Praxis Precision Medicines Inc do?
Who are the key executives at Praxis Precision Medicines Inc?
Nicholas Galakatos is the director of Praxis Precision Medicines Inc. Other key executives at Praxis Precision Medicines Inc include Chief Executive Officer Marcio Souza , Chief Financial Officer Timothy Edwin Kelly , and Principal Accounting Officer Lauren Mastrocola .
Praxis Precision Medicines Inc (PRAX) Insider Trades Summary
Over the past 18 months, Nicholas Galakatos made no insider transaction in Praxis Precision Medicines Inc (PRAX). Other recent insider transactions involving Praxis Precision Medicines Inc (PRAX) include a net purchase of 80,002 shares made by Marcio Souza , a net purchase of 50,000 shares made by Dean J Mitchell , and a net purchase of 14,500 shares made by Jill Desimone .
In summary, during the past 3 months, insiders sold 0 shares of Praxis Precision Medicines Inc (PRAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Praxis Precision Medicines Inc (PRAX) were sold and 10,167 shares were bought by its insiders, resulting in a net purchase of 10,167 shares.
Praxis Precision Medicines Inc (PRAX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Praxis Precision Medicines Inc Insider Transactions
Nicholas Galakatos Mailing Address
Above is the net worth, insider trading, and ownership report for Nicholas Galakatos. You might contact Nicholas Galakatos via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.